Graphite Bio IncGRPHvoluntarily paused the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) following a serious adverse event in the first patient dosed with nula-cel.
The company concluded that the event is likely related to the study treatment.
As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.
The decision by Graphite Bio to voluntarily pause the CEDAR study follows a serious and unexpected adverse event of prolonged low blood cell counts (pancytopenia) requiring ongoing transfusion and growth factor support in the first patient dosed with nula-cel.
The patient achieved study-defined neutrophil engraftment and has shown no evidence of myelodysplasia, a rare type of blood cancer.
Graphite Bio no longer expects to file an investigational new drug application for GPH102 in beta-thalassemia by mid-2024. The company is also working to identify operational efficiencies to extend its cash position to at least 2026.
Graphite Bio will provide a business update by the end of the first quarter of 2023.
Price Action: GRPH shares are down 47.70% at $1.60 during the premarket session on the last check Friday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
